'A Highly Efficient, Clinical Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity'
GAITHERSBURG, Md., Dec. 4 /PRNewswire/ --MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Joseph C. Fratantoni, MD, Vice President Medical Affairs and Clinical Development at MaxCyte, will give a presentation on a breakthrough approach to developing cancer therapies at the 50th ASH Annual Meeting to be held at the Moscone Center in San Francisco, December 6-9, 2008. Dr. Fratantoni's presentation is entitled, "A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity" and will be held during the Tumor Immunotherapy Poster II Session on Monday, December 8, 2008 at 5:30 PM - 7:30 PM in Moscone Center, Hall A (Poster Board no.: III-976).
The presentation will discuss how chimeric tumor-antigen receptor mRNA loaded peripheral blood mononuclear cells offer the potential to develop customizable, engineered outpatient transfusion medicine products for cancer therapies without the infrastructure and logistical challenges associated with development of traditional cellular therapy products. This represents a paradigm shift in current cancer therapy approaches and utilizes current transfusion medicine infrastructure present in any major hospital.
About MaxCyte
MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte's cell transfection technology platform
enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.
MaxCyte's licenses its cell modification technology to companies developi
'/>"/>
| SOURCE MaxCyte, Inc. Copyright©2008 PR Newswire. All rights reserved |